EUCTR2007-003976-20-IT进行中(未招募)不适用
A randomised, double blind, placebo and active controlled, parallel group study to evaluate the analgesic effect of a single dose of GRC 6211, a TRPV1 receptor antagonist on pain following third molar tooth extraction. - ND
GLENMARK PHARMACEUTICALS SA0 个研究点开始时间: 2007年10月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male and female patients (18-50 years of age), previously scheduled for extraction of at
- •least one 3rd impacted mandibular molar tooth under local anaesthesia, and who are
- •otherwise healthy, will be recruited.
- •-females of childbearing
- •potential must be using adequate contraception.
- •-Patient complaining of moderate to severe pain on Verbal Rating Scale (VRS)
- •within 3 hours after the end of surgery.
- •-Patient agreeing not to take analgesics other than protocol defined rescue
- •analgesics during treatment period (up to 24 hrs post dose).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Patient who has a history or presence of significant organ disease or mental
- •-Patient who has been exposed to analgesics within 24 hours prior to the start of surgery.
- •-Patient who is unable to refrain from alcohol, psychoactive drugs, and sedatives
- •(e.g. benzodiazepines) within 48 hours prior from the start of surgery and for 48hrs post dose.
- •-Patient who is judged by the investigator not to be a suitable candidate for
- •ibuprofen or co-efferalgan therapy based on medical history;
- •-Patient has a history of drug or alcohol abuse. Abuse of alcohol is defined as an
- •average weekly intake of greater than 21 units or an average daily intake of
- •greater than three units for males and intake greater than 14 units per week or an
- •average daily intake of greater than two units for females.
- •-History of sensitivity to any of the study medications, or components or a history
- •-Has a supine systolic blood pressure which is outside the range of 90 to 140
- •mmHg, supine diastolic blood pressure is outside the range of 50 to 90 mmHg or
- •supine heart rate is outside the range 45-100 bpm.
- •-QTc interval ≥450ms,a family history of Long QT syndrome, the use of concomitant medications that prolong the QT/QTc interval.
研究者
相似试验
进行中(未招募)
不适用
A randomized, double blind, placebo and active controlled, parallel groupstudy to evaluate the safety and efficacy of 6-week treatment with oral doses of50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in steroid-naïvepatients with persistent asthmaEUCTR2010-023326-20-LVBoehringer Ingelheim RCV GmbH & Co KG390
进行中(未招募)
不适用
A randomized, double blind, placebo and active controlled, parallel groupstudy to evaluate the safety and efficacy of 6-week treatment with oral doses of50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d. BI 671800 ED in steroid-naïvepatients with persistent asthmaEUCTR2010-023326-20-EEBoehringer Ingelheim RCV GmbH & Co KG390
进行中(未招募)
1 期
A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and 3 mg ZK 283197, 1 mg 17ß-estradiol and placebo once daily for 8 weeks in postmenopausal women with hot flushesVasomotor symptoms (hot flushes)EUCTR2007-001791-36-GBBayer Schering Pharma AG
进行中(未招募)
不适用
A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and3 mg ZK 283197, 1 mg 17ß-estradiol and placebo once daily for 8 weeks in postmenopausal women with hot flushesEUCTR2007-001791-36-NLBayer Schering Pharma AG112
进行中(未招募)
不适用
A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and3 mg ZK 283197, 1 mg 17ß-estradiol and placebo once daily for 8 weeks in postmenopausal women with hot flushesEUCTR2007-001791-36-DEBayer Schering Pharma AG118
